Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$27.99 USD
-0.22 (-0.78%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $27.98 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
RPRX 27.99 -0.22(-0.78%)
Will RPRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RPRX
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
Royalty Pharma (RPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
RPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q2 Earnings, Beyond Revenue and EPS
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Other News for RPRX
10 Health Care Stocks With Whale Alerts In Today's Session
RPRX Breaks Above 3% Yield Territory
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update
Dividend Champion, Contender, And Challenger Highlights: Week Of September 8
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement